文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

ROX指数预测Covid-19相关低氧性急性呼吸衰竭经鼻高流量氧疗结局的性能

ROX index performance to predict high-flow nasal oxygen outcome in Covid-19 related hypoxemic acute respiratory failure.
PubMed 文献 · Ann Intensive Care · 2024-01-18
一句话结论在Covid-19急性呼吸衰竭患者中,ROX指数判别HFNO失败与成功的准确性技术上可接受但临床价值低,SAPS II和肺部损伤范围预测插管风险更有用。

该多中心回顾性队列研究纳入99例首次接受HFNO治疗的Covid-19急性呼吸衰竭患者,其中49例HFNO失败(46例插管、3例插管前死亡)。HFNO启动时(H0)ROX指数灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%);H12以4.88为界值时灵敏度29%(95%CI 14-48%)、特异度90%(95%CI 78-97%),Youden指数给出的8.73界值灵敏度87%(95%CI 70-96%)、特异度45%(95%CI 31-60%)。单因素分析H0 ROX指数与HFNO失败相关(p=0.0005),但多因素分析中SAPS II(p=0.0003)和肺部损伤影像学范围(p=0.0263)而非ROX指数可预测HFNO失败。作者认为ROX指数界值似乎具有人群特异性,判别能力临床价值低。

要点

  • 99例Covid-19急性呼吸衰竭首次HFNO患者中49例失败(46例插管、3例插管前死亡)。
  • H0 ROX指数以Youden指数为界值时灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%)。
  • H12以4.88为界值时灵敏度仅29%(95%CI 14-48%)、特异度90%(95%CI 78-97%)。
  • 多因素分析中SAPS II(p=0.0003)和肺部损伤影像学范围(p=0.0263)预测HFNO失败,ROX指数未进入。
  • 作者认为ROX指数界值似乎具有人群特异性,判别HFNO失败与成功的临床能力低。

适用人群与场景

  • 多中心回顾性队列中连续纳入的Covid-19急性呼吸衰竭患者,共筛查218例,其中99例首次接受HFNO治疗。

诊断标准与关键阈值

  • ROX指数=SpO2/FiO2与呼吸频率的比值。
  • H0以Youden指数确定界值,灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%)。
  • H12以4.88为界值,灵敏度29%(95%CI 14-48%)、特异度90%(95%CI 78-97%)。
  • H12 Youden指数界值为8.73,灵敏度87%(95%CI 70-96%)、特异度45%(95%CI 31-60%)。

研究设计与关键结果

  • 研究类型为多中心回顾性队列研究,筛查218例Covid-19急性呼吸衰竭患者,99例首次接受HFNO,其中49例HFNO失败(46例插管、3例插管前死亡)。
  • H0 ROX指数灵敏度63%(95%CI 48-77%)、特异度76%(95%CI 62-87%);H12以4.88为界值灵敏度29%(95%CI 14-48%)、特异度90%(95%CI 78-97%);H12 Youden指数界值8.73时灵敏度87%(95%CI 70-96%)、特异度45%(95%CI 31-60%)。
  • 单因素分析H0 ROX指数与HFNO失败相关(p=0.0005)。
  • 多因素分析显示SAPS II(p=0.0003)和肺部损伤影像学范围(p=0.0263)而非ROX指数可预测HFNO失败。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 作者结论:ROX指数界值似乎具有人群特异性,ROX指数判别HFNO失败与成功的准确性技术上可接受但临床能力低;SAPS II和入ICU时肺部损伤似乎比ROX指数更有用于预测插管风险。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ROX指数界值似乎具有人群特异性,在Covid-19急性呼吸衰竭患者中判别HFNO失败与成功的临床能力低。
  • 作者认为SAPS II和入ICU时肺部损伤影像学范围似乎比ROX指数更有用于预测插管风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Given the pathophysiology of hypoxemia in patients with Covid-19 acute respiratory failure (ARF), it seemed necessary to evaluate whether ROX index (ratio SpO2/FiO2 to respiratory rate) could accurately predict intubation or death in these patients initially treated by high-flow nasal oxygenation (HFNO). We aimed, therefore, to assess the accuracy of ROX index to discriminate between HFNO failure (sensitivity) and HFNO success (specificity).

METHODS: We designed a multicentre retrospective cohort study including consecutive patients with Covid-19 ARF. In addition to its accuracy, we assessed the usefulness of ROX index to predict HFNO failure (intubation or death) via logistic regression.

RESULTS: Among 218 ARF patients screened, 99 were first treated with HFNO, including 49 HFNO failures (46 intubations, 3 deaths before intubation). At HFNO initiation (H0), ROX index sensitivity was 63% (95%CI 48-77%) and specificity 76% (95%CI 62-87%) using Youden's index. With 4.88 as ROX index cut-off at H12, sensitivity was 29% (95%CI 14-48%) and specificity 90% (95%CI 78-97%). Youden's index yielded 8.73 as ROX index cut-off at H12, with 87% sensitivity (95%CI 70-96%) and 45% specificity (95%CI 31-60%). ROX index at H0 was associated with HFNO failure (p = 0.0005) in univariate analysis. Multivariate analysis showed that SAPS II (p = 0.0003) and radiographic extension of pulmonary injuries (p = 0.0263), rather than ROX index, were predictive of HFNO failure.

CONCLUSIONS: ROX index cut-off values seem population-specific and the ROX index appears to have a technically acceptable but clinically low capability to discriminate between HFNO failures and successes in Covid-19 ARF patients. In addition, SAPS II and pulmonary injuries at ICU admission appear more useful than ROX index to predict the risk of intubation.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Girault C, Bubenheim M, Boyer D, et al. ROX index performance to predict high-flow nasal oxygen outcome in Covid-19 related hypoxemic acute respiratory failure. Ann Intensive Care. 2024. PMID: 38236356. doi:10.1186/s13613-023-01226-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。